MNAC13
MNAC13 is a kind of mouse IgG1 chimeric antibody, targeting to human TrkA. MNAC13 inhibits the NGF dependent signaling pathway by specifically binding to TrkA receptors. MNAC13 has good analgesic effect and long-lasting efficacy. MNAC13 can be used for researches on inflammatory and chronic pain.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
|
TrkA |
MNAC13 (200-300 μg/mL, 1 h) specifically binds TrkA and leads to inhibition of NGF-dependent signaling in 3T3 cells overexpressing TrkA[1].
MNAC13 (4 μg/mL, 4 days) effectively blocks NGF induced survival and axonal growth of PC12 cells[2].
MNAC13 (2 or 20 ng/mL) specifically binds to TrkA immune adhesin, but does not bind to TrkB in TrkA-BALB/C 3T3 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:3T3 cells overexpressing TrkA
-
Concentration:200-300 μg/mL
-
Incubation Time:1 h
-
Result:Significantly inhibited the phosphorylation of TrkA and the phosphorylation level of downstream signaling molecule PLCγ1.
MNAC13 (30-70 μg; i.p.; once daily; from day 3 to day 10) significantly reduces neuropathic pain and exhibits long-lasting effects in the chronic constriction injury (CCI) CD1 male mice[1].
MNAC13 (1 μg; i.p.; single dose; 15 min before the test) has a significant synergistic analgesic effect combinated with opioid drugs in the 5 % formalin solution injected CD1 male mice[1].
MNAC13 blocks the effect of TrkA on basal forebrain cholinergic neurons (BFCNs) more significantly and persistently than blocking NGF in MNAC13 hybridoma cells injected Wistar rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5 % formalin solution injected CD1 male mice (30-40 g)[1]
-
Dosage:0.9, 1.875, 3.75, 7.5, 15, 30 and 60 μg
-
Administration:Subcutaneous injection (s.c.) of 0.9, 1.875, 3.75, 7.5, 15, 30 and 60 μg; Intraperitoneal injection (i.p.) of 15μg
-
Result:Significantly reduced late stage licking behavior and was also effective for early pain at 15 μg.
-
Animal Model:CCI CD1 male mice (30-40 g)[1]
-
Dosage:30, 50 and 70 μg
-
Administration:Intraperitoneal injection (i.p.); once daily from day 3 to day 10
-
Result:Significantly reduced mechanical allodynia and has long-lasting effects.
-
Animal Model:5 % formalin solution injected CD1 male mice (30-40 g)[1]
-
Dosage:1 μg; combinated with morphine (1 mg/kg) or fentanyl (5 μg/kg)
-
Administration:Intraperitoneal injection (i.p.); 15 min before the test
-
Result:Generated significant synergistic analgesic effect.
Acted on the central nervous system and naloxone failed to reverse the synergistic effect.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Ugolini G, et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2985-90. [Content Brief]
[2]. Cattaneo A, et al. Functional blockade of tyrosine kinase A in the rat basal forebrain by a novel antagonistic anti-receptor monoclonal antibody. J Neurosci. 1999 Nov 15;19(22):9687-97. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz